This open-label, single-arm, phase 1b dose escalation and expansion study (ClinicalTrials.gov identifier NCT04178460) explored the safety, tolerability, and antitumor activity of tebotelimab, a programmed cell death protein 1 Ã— lymphocyte-activation gene 3 bispecific monoclonal antibody, in combination with niraparib, a poly(adenosine diphosphate ribose) polymerase inhibitor, in patients with gastric cancer, triple-negative breast cancer (TNBC), biliary tract carcinoma (BTC), and endometrial carcinoma.
